Nuclein is a biotechnology company that develops the polymerase chain reaction test device for infectious diseases.
Nuclein has raised $19.1M in total funding. The most recent round was Debt Financing. The last funding was announced in October 2025.
Nuclein's investors include Trinity Investors, Trinity Private Equity Group.
Nuclein is headquartered in Austin, United States.
Nuclein is a biotechnology company that develops the polymerase chain reaction test device for infectious diseases.
Nuclein is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nuclein — Funding & Investors." VCBacked, October 14, 2025, https://www.vcbacked.co/company/nuclein. Accessed August 14, 2026.
VCBacked. (2025). Nuclein — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/nuclein
{{cite web |title=Nuclein — Funding & Investors |url=https://www.vcbacked.co/company/nuclein |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated